Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/06—Dipeptides
  • C07K5/06008—Dipeptides with the first amino acid being neutral
  • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
  • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
  • Y02P20/00—Technologies relating to chemical industry
  • Y02P20/50—Improvements relating to the production of bulk chemicals
  • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

• the present invention relates to an epoxy succinic acid derivative useful as a medicament, and more particularly, to an epoxy succinic acid derivative that specifically inhibits cathepsin B and an intermediate for producing the same.
• the calcium-dependent neutral proteases (CANPs) belonging to the cystine protease, cathepsin B, cathepsin L, etc., are muscles such as muscular dystrophy and dystrophy myopathy which are intractable diseases. It is said to be involved in the degradation of muscle structural proteins in destructive diseases.
• N (L—3—trans-carboxyloxysilane-1-2—carbonyl) —one L mouthful isiburea gumati Agric. Biol. Chemistry, Vol. 42, Vol. 52 3-5 P. 28 (1978)]
• epoxy succinic acid derivatives such as epoxy disuccinic acid disulfide derivatives (British Patent No. 2,046, 730) are known.
• epoxy succinic acid derivatives that specifically inhibit only one of the cystine proteases have not been developed. unknown.
• the present inventors have conducted intensive studies on compounds having an epoxy ring, and as a result, have found a compound that specifically inhibits catebucin B, which is different from known compounds, and completed the present invention. That is, the present invention relates to formula I
• R 1 represents an alkyl group having 1 to 10 carbon atoms, a phenyl group or a benzyl group.
• R 1 represents an alkyl group having 1 to 10 carbon atoms, a phenyl group or a benzyl group.
• Still another invention relates to a compound of formula I which is an intermediate for the preparation of a compound of formula I
• R 1 is as defined above, and R 2 is a carboxyl-protecting group. It is a derivative.
• the alkyl group having 1 to 10 carbon atoms is a linear, branched or cyclic alkyl group, for example, a methyl group, an ethyl group, an n-propyl group, — Butyl, n—pentyl, isopropyl, isobutyl, t—butyl, cyclohexyl, etc., preferably n-propyl, n—pentyl And so on.
• the term "protecting group for carboxyl group” means a protecting group for carboxyl group usually used in the field of peptide synthesis chemistry, for example, benzyl group, noramethoxy benzyl group, No ,. Lanitrobenzyl, t-butyl, benzhydryl, trimethylsilyl, methyl, and ethyl groups.
• Pharmaceutically acceptable salts in the present invention include, for example, salts with inorganic bases including sodium, potassium, magnesium, ammonium and the like, and triethylamine. Salts with organic bases and basic amino acids such as cyclohexylamine, arginine and lysine, salts with mineral acids such as sulfuric acid, hydrochloric acid and phosphoric acid, or acetic acid Examples include salts with organic acids such as lactic acid, tartaric acid, fumaric acid, maleic acid, glutamic acid, and aspartic acid, and salts with acidic amino acids.
• the compound of the present invention can be produced, for example, by the following method (wherein, R 1 and R 2 have the same meanings as described above, and R 3 has the same meaning as R 2. Or a protecting group for a different carboxyl group.)
• Step a Chemical Pharmaceutical Purtin, Vol. 35, Vol. 109, No. 109-111, p.
• the epoxy succinic acid derivative represented by the formula M which can be produced according to the method described in (1) above, is dissolved in a solvent such as black form, ethyl acetate, N, N-dimethylformamide, etc.
• the compound of formula IV "is reacted with 1.0 to 2.0 molar equivalents of the amide to give the compound of formula V.
• Step b The protecting group for the carboxyl group of the compound represented by the formula V is converted to a compound such as palladium carbon, phenol in a solvent such as methanol, ethanol, N, N-dimethylformamide.
• Catalytic reduction method using a catalyst such as radium black, power-transfer-transfer-hydrogenation (CTH) method, or trifluoroacetic acid, methansulphonic acid,
• CTH power-transfer-transfer-hydrogenation
• a method commonly used in the field of peptide synthesis chemistry such as a hydrolysis method using an acid such as hydrobromic acid or hydrochloric acid, or an alkali such as sodium hydroxide or potassium hydroxide.
• the compound is removed under the conditions to obtain a compound represented by the formula VI.
• Step c A dipeptide derivative W produced by a conventional method in the field of peptide synthetic chemistry from isoloicin and proline and a compound represented by the formula VI in the range of 1.0 to 2.0.
• the molar equivalents of N, N'-dicyclohexyl carbodiimide, N-ethyl-N 'in solvents such as chloroform, ethyl acetate, N, N-dimethylformamide, etc.
• Carbodi such as carbodiimide hydrochloride Condensation is carried out using a method and conditions commonly used in the field of peptide synthesis chemistry, such as a method using a amide compound, a mixed acid anhydride method, an acid halide method, an acid azide method, and an active ester method.
• Step d The protecting group for the carboxyl group of the compound represented by the formula] is removed by the same method and under the same conditions as in Step b to obtain the compound of the present invention represented by the formula I.
• the amine derivative represented by the formula IV and the dipeptide derivative represented by the formula W may be a salt with hydrochloric acid, sulfuric acid, p-toluenesulfonate, etc.
• the reaction can be carried out in the presence of a base such as ethylamine, N, N-diisopropylpropylamine, N-methylmorpholine, pyridin and the like.
• the compounds of the formula I thus obtained hardly inhibited the cysteine proteases, papine and CANP, but specifically and strongly inhibited cathepsin B. Test examples are shown below.
• the inhibitory activity against pappine, CANP and cathepsin B was measured by the following method, and the results are shown in Table 1.
• the fluorescence of the released 7-amino-4-methylcoumarin was measured at an excitation wavelength of 380 nm and an emission wavelength of 440 nm using a Shimadzu fluorometer RF-500.
• the concentration of the test drug required for 50% inhibition was calculated from the inhibition rate calculated using the value measured in the same manner without adding the test drug, and IC 5 was obtained . It is shown as a value.
• the mixture was centrifuged at 3000 X g for 5 minutes, and the absorbance at 280 nm of the supernatant was measured. 10% trichloroacetic acid was added before adding CANP, and the blank value measured in the same manner was subtracted to determine the residual activity. The concentration of the test drug required for 50% inhibition was calculated from the inhibition rate calculated using the value measured in the same manner without adding the test drug, and IC 5 was determined . It is shown as a value.
• test drugs in the table indicate the compounds obtained in the following Examples.
• n-propylammonium, isopropylamine, t-butylamine, isobutylamine were replaced by n-propylamine, respectively.
• Lure Min n—Butylamine, Isoamylamine, n—Amilamine, n—Hexylamine, n—Heptylamine, Benzylamine, Anilin or Sai
• the compounds shown in Table 2 below were obtained using chlorohexylamine.
• Example 2 Based on the procedures and reaction conditions disclosed in Example 1b, the corresponding compounds shown in Table 3 below were obtained from the compounds 2a to 13a in Table 2.
• Example 1C Based on the operation and reaction conditions disclosed in Example 1C, the corresponding compounds shown in Table 4 below were obtained from the compounds 2b to 13b in Table 3 respectively.
• Example 1d Based on the operation and reaction conditions disclosed in Example 1d, the corresponding compounds shown in Table 5 below were obtained from the compounds 2cl3c in Table 4 respectively.
• the compound of the formula 1 is orally or parenterally administered in administration preparations such as tablets, pills, capsules, granules and injections.
• administration preparations such as tablets, pills, capsules, granules and injections.
• Each of the above-mentioned preparations is manufactured according to a conventional preparation technique, and additives such as a usual bulking agent, a binder, a pH adjuster, and a solubilizer can be added.
• the dosage of the compound of formula I for the treated patient will vary depending on the patient's age, the type and condition of the illness, etc., but is generally from 1 to 100 mg / day. It can be administered in several divided doses.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Biochemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Molecular Biology (AREA)
• Genetics & Genomics (AREA)
• Biophysics (AREA)
• Pharmacology & Pharmacy (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• General Chemical & Material Sciences (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Epoxy Compounds (AREA)
• Peptides Or Proteins (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (1)

Family

ID=17364955

Family Applications (1)

Country Status (9)

Families Citing this family (7)

Citations (2)

Family Cites Families (2)

• 1990
  • 1990-09-29 JP JP2261657A patent/JP2808877B2/ja not_active Expired - Fee Related
• 1991
  • 1991-09-27 DE DE69123757T patent/DE69123757T2/de not_active Expired - Fee Related
  • 1991-09-27 US US08/030,089 patent/US5281717A/en not_active Expired - Fee Related
  • 1991-09-27 ES ES91917015T patent/ES2098370T3/es not_active Expired - Lifetime
  • 1991-09-27 WO PCT/JP1991/001288 patent/WO1992006090A1/ja not_active Ceased
  • 1991-09-27 KR KR1019930700858A patent/KR0167084B1/ko not_active Expired - Fee Related
  • 1991-09-27 AT AT91917015T patent/ATE146481T1/de not_active IP Right Cessation
  • 1991-09-27 EP EP91917015A patent/EP0555479B1/en not_active Expired - Lifetime
  • 1991-09-27 CA CA002092919A patent/CA2092919C/en not_active Expired - Fee Related

Patent Citations (2)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events